Study reveals PGK1 enzyme as therapeutic target for deadliest brain cancer

February 23, 2017

Discovery of a dual role played by the enzyme phosphoglycerate kinase 1 (PGK1) may indicate a new therapeutic target for glioblastoma, an often fatal form of brain cancer, according to researchers at The University of Texas MD Anderson Cancer Center.

Findings published in the Feb. 23 online issue of Molecular Cell determined PGK1 as instrumental in regulating both cell metabolism and , a cellular process crucial to tumor development and maintenance. In previous studies, PGK1 was shown to play a role in coordinating cellular activities tied to cancer metabolism and brain tumor formation, and is associated with tumor metastasis and drug resistance.

"Our finding that PGK1 acts as both a glycolytic enzyme and a protein kinase in cell metabolism, autophagy, and cell proliferation greatly enhances our understanding of protein enzymes controlling cellular function," said Zhimin Lu, M.D., Ph.D., professor of Neuro-Oncology. "Because it regulates both autophagy and , PGK1 proves its significance in maintaining , thus offering a potential new approach for cancer treatment."

Lu's team found that PGK1 unexpectedly impacts the protein Beclin1 through phosphorylation, which modulates protein function. Beclin1 plays a central role in autophagy, a "recycling" process allowing cells to thrive even when starved of nutrients and/or oxygen. Autophagy has been increasingly linked to cancer since it permits tumors to access vital energy sources and necessary to grow and spread.

The researchers observed that lack of oxygen and the essential amino acid glutamine resulted in a complex protein-related chain of events where PGK1 phosphorylates Beclin1, which is required for autophagy and brain tumor development. The process is thought to be one reason why glioblastoma patients generally have poor prognoses.

"Upregulated tumor-protective autophagy is one of the reasons for cancer treatment resistance," said Lu. "These findings suggest that approaches inhibiting PGK1-regulated autophagy are likely to increase efficacy. Further investigations into this area of research are underway."

Explore further: PGK1 protein promotes brain tumor formation and cancer metabolism

Related Stories

PGK1 protein promotes brain tumor formation and cancer metabolism

March 3, 2016
PGK1, a glycolytic enzyme, has been found to play a role in coordinating cellular processes crucial to cancer metabolism and brain tumor formation, according to results published in today's online issue of Molecular Cell. ...

Study suggests that autophagy inhibitors could improve efficacy of chemotherapies

October 24, 2016
Chemotherapies treat cancer by killing tumor cells, but certain types of chemotherapy can also drive an immune system response to target and destroy the remaining tumor cells.

Role for autophagic cellular degradation process in maintaining genomic stability

November 29, 2016
Centrosomes play an essential role in cell division by organizing the protein framework on which chromosomes assemble and then separate prior to division into daughter cells. Centrosomes are made up of a pair of centrioles, ...

Inducing metabolic catastrophe in cancer cells

August 31, 2015
A study published in The Journal of Cell Biology describes a way to force cancer cells to destroy a key metabolic enzyme they need to survive.

Protein induces self-destruction in cancer cells

January 21, 2015
The role of a phosphatase protein in promoting the self-destruction of healthy cells and the progression of ovarian cancer has been identified by A*STAR researchers. Known to be overexpressed in cancer cells, the protein, ...

Recommended for you

Tracking how multiple myeloma evolves by sequencing DNA in the blood

December 10, 2017
Although people with multiple myeloma usually respond well to treatment, the blood cancer generally keeps coming back. Following genetic changes in how the disease evolves over time will help to understand the disease and, ...

Landmark CAR-T cancer study published

December 10, 2017
Loyola University Medical Center is the only Chicago center that participated in the pivotal clinical trial of a groundbreaking cancer treatment that genetically engineers a patient's immune system to attack cancer cells.

Study finds emojis promising tool for tracking cancer patients' quality of life

December 10, 2017
In findings presented to the American Society of Hematology, Mayo Clinic researchers found that using emojis instead of traditional emotional scales were helpful in assessing patients' physical, emotional and overall quality ...

Study explores use of checkpoint inhibitors after relapse from donor stem cell transplant

December 10, 2017
Immunotherapy agents known as checkpoint inhibitors have shown considerable promise in patients with hematologic cancers who relapse after a transplant with donor stem cells. Preliminary results from the first clinical trial ...

Blood test may help predict which breast cancers will recur

December 8, 2017
A blood test five years after breast cancer treatment helped identify some women who were more likely to relapse, long before a lump or other signs appeared, a preliminary study found.

Alcohol-abuse drug Antabuse kills cancer cells

December 8, 2017
A new study in Nature by an international team including researchers from Karolinska Institutet, reports that the alcohol-abuse drug Antabuse is effective against cancer. The study also identifies a potential mechanism of ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.